(R)-4-(Methoxymethyl)-2,2-dimethyl-1,3-dioxolane | 51575-05-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-4-(Methoxymethyl)-2,2-dimethyl-1,3-dioxolane
• 英文别名: 4(R)-methoxymethyl-2,2-dimethyl-1,3-dioxolane；(4R)-4-(methoxymethyl)-2,2-dimethyl-1,3-dioxolane
• CAS: 51575-05-4
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: ATRLVVVJFBQMEX-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-4-(Methoxymethyl)-2,2-dimethyl-1,3-dioxolane 在 amberlyst 作用下， 以 甲醇 为溶剂， 反应 25.0h， 以67.5 mg的产率得到(S)-3-methoxypropane-1,2-diol
  参考文献：
  名称：

  Non-naturally Occurring Regio Isomer of Lysophosphatidylserine Exhibits Potent Agonistic Activity toward G Protein-Coupled Receptors

  摘要：

  Lysophosphatidylserine (LysoPS), an endogenous ligand of G protein-coupled receptors, consists of L-serine, glycerol, and fatty acid moieties connected by phosphodiester and ester linkages, respectively. An ester linkage of phosphatidylserine can be hydrolyzed at the 1-position or at the 2-position to give 2-acyl lysophospholipid or 1-acyl lysophospholipid, respectively. 2-Acyl lysophospholipid is in nonenzymatic equilibrium with 1-acyl lysophospholipid in vivo. On the other hand, 3-acyl lysophospholipid is not found, at least in mammals, raising the question of whether the reason for this might be that the 3-acyl isomer lacks the biological activities of the other isomers. Here, to test this idea, we designed and synthesized a series of new 3-acyl lysophospholipids. Structure- activity relationship studies of more than 100 "glycol surrogate" derivatives led to the identification of potent and selective agonists for LysoPS receptors GPR34 and P2Y10. Thus, the non-natural 3-acyl compounds are indeed active and appear to be biologically orthogonal with respect to the physiologically relevant 1- and 2-acyl lysophospholipids.

  DOI：

  10.1021/acs.jmedchem.0c01126
• 作为产物：
  描述：

  (R)-(-)-甘油醇缩丙酮 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 (R)-4-(Methoxymethyl)-2,2-dimethyl-1,3-dioxolane
  参考文献：
  名称：

  Oxazolidinone derivatives, their preparation and therapeutical use

  摘要：

  本发明涉及异吲哚衍生物，更具体地是在3位被吲唑、苯并异噁唑或苯并异硫唑环系统取代的5-(羟甲基)噁唑啉-2-酮衍生物，以及它们的制备方法和在治疗中的应用。

  公开号：

  US05843975A1

文献信息

• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。
• Oxazolidin-2-one derivatives, preparation method therefor and
  申请人：Synthelabo

  公开号：US05969146A1

  公开（公告）日：1999-10-19

  Compounds derived from oxazolidin-2-one of formula (I) ##STR1## in which: R.sub.1 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a fluoroalkyl group, a hydroxyfluoroalkyl group, a cyanoalkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenylmethyl group or an R.sub.3 A- group in which R.sub.3 is a cycloalklyl or cyclooxyalkyl group which is unsubstituted or substituted by a hydroxyl group and A is a --CH.sub.2 or --CH.sub.2 --CH.sub.2 radical, R.sub.2 represents a hydrogen atom or a methyl group, X represents an oxygen or sulphur atom or an NR.sub.4 group where R.sub.4 is an alkyl group or a hydrogen atom, and Z represents an oxygen atom or a --CH.dbd.CH or --CH.sub.2 --CH.sub.2 group, their process of preparation and their applications in therapeutics.

  从氧唑啉-2-酮衍生的化合物，其化学式为（I）##STR1##其中：R.sub.1代表氢原子、烷基、羟基烷基、氟烷基、羟基氟烷基、氰基烷基、取代或未取代苯基、取代或未取代苯甲基或R.sub.3 A-基团，其中R.sub.3是未取代或取代的环烷基或环氧烷基，A是--CH.sub.2或--CH.sub.2--CH.sub.2基团，R.sub.2代表氢原子或甲基，X代表氧原子、硫原子或NR.sub.4基团，其中R.sub.4是烷基或氢原子，Z代表氧原子或--CH.dbd.CH或--CH.sub.2--CH.sub.2基团，它们的制备过程及在治疗学中的应用。
• Compounds derived from oxazolidin-2-one and preparation and
  申请人：Synthelabo

  公开号：US05925662A1

  公开（公告）日：1999-07-20

  Derivatives of oxazolidin-2-one of general formula (I) ##STR1## in which: n is equal to 0 or 1, R.sub.1 represents a cyano group, an alkyl group or a fluoroalkyl group, R.sub.2 represents a hydrogen atom or a hydroxyl group, and R.sub.3 represents a hydrogen atom or a methyl group. Application in therapeutics.

  一般式为(I)的噁唑烷-2-酮衍生物##STR1##其中：n等于0或1，R.sub.1代表氰基，烷基或氟烷基，R.sub.2代表氢原子或羟基，R.sub.3代表氢原子或甲基。在治疗学中的应用。
• Compounds derived from 3-(benzofuran-5-yl)oxazolidin-2-one, preparation
  申请人：Synthelabo

  公开号：US06143772A1

  公开（公告）日：2000-11-07

  Compounds derived from 3-(benzofuran-5-yl) oxazolidin-2-one, of general formula (I) ##STR1## in which: R.sub.1 represents a phenyl group, a phenylmethyl group, an alkyl group or a fluoroalkyl group, and R.sub.2 represents a hydrogen atom or a methyl group. Application in therapeutics.

  从3-(苯并呋喃-5-基)噁唑啉-2-酮衍生的化合物，通式为(I) ##STR1## 其中：R.sub.1代表苯基，苯甲基，烷基或氟烷基；R.sub.2代表氢原子或甲基。在治疗学中的应用。
• HSP90 INHIBITORS
  申请人：Chen Young K.

  公开号：US20110053873A1

  公开（公告）日：2011-03-03

  The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及一种HSP90抑制化合物，其化学式为：（I），其中变量如本文所定义。本发明还涉及包含此类化合物的制药组合物、工具箱和制造物品；用于制备该化合物的方法和中间体；以及使用该类化合物的方法。